Beyondspring (BYSI) Stock
Early stage biotech developing cancer drugs. Here's the price, business snapshot, and what's worth knowing about Beyondspring in August 2026.
BeyondSpring Inc (BYSI) is a small-cap, clinical-stage biotechnology company focused on oncology drug development. With a market capitalisation of about $88.71 million, the company’s near-term progress is driven largely by clinical trial readouts, regulatory interactions and potential collaborations or licensing deals. Investors should be aware that outcomes hinge on trial data and approvals, making the share price potentially volatile. As a development-stage business, BeyondSpring may require additional financing, which can dilute shareholders. This summary is for general educational purposes only and not personalised investment advice. The stock may suit investors with a higher risk tolerance who understand biotech-specific risks; values can rise or fall and past performance does not predict future results.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Beyondspring's stock with a target price of $1.25, indicating modest growth potential.
Financial Health
Beyondspring Inc is showing modest cash flow, indicating stability but with room for improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical-stage pipeline
Trial readouts and regulatory progress are central to valuation; results can be binary and may cause significant share movement.
Potential catalysts
Upcoming study results, approvals or partnerships could change the outlook, though timings and outcomes are uncertain.
Small-cap dynamics
Lower market capitalisation can create higher volatility and liquidity constraints; suitable for investors who accept greater risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
